海外の治験の状況「膀胱がん」での検索結果
83件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer. - Novel chemo-immunotherapy for non-muscle invasive bladder cancer
- Patients with intermediate/high risk non-muscle invasive bladder cancer (NMIBC) • intermediate risk tumours – Ta, T1 Grade 1, Grade 2, multifocal and tumours larger than 3 cm • high risk tumours – T1, Grade 3, multifocal or highly recurrent tumours and all cases of CIS (Carcinoma in situ) MedDRA version: 14.1 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Belgium
- 2011-02-11
Authorised
- Obturator nerve anesthesia guided by ultrasound to facilitate complete resection of bladder tumor
- Bladder cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2015-09-11
Authorised
- A Phase II Trial of MK-3475 in Subjects with Bladder Cancer
- advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. MedDRA version: 17.1 Level: LLT Classification code 10046714 Term: Urothelial carcinoma bladder System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, Denmark, Hungary, Israel, Italy, Puerto Rico, Spain, United States
- 2014-11-03
Authorised
- EFFECT OF HYPERTHERMIA IN THE TREATMENT OF SUPERFICIAL BLADDER CANCER
- NON MUSCULAR INVASIVE BLADDER CANCER WITH INTERMEDIATE RISK OF RECURRENCE;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2013-08-01
Authorised
- Study to Individualize with DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer patients.
- The study aims to evaluate the activity of cisplatin based neoadjuvant chemotherapy compared with the combination of durvalumab and tremelimumab to T2-T4a bladder cancer patients according to the pro-inflammatory signature. MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2018-06-20
Authorised
- A study of enfortumab vedotin in patients with locally advanced or metastatic urothelial bladder cancer
- Patients with locally advanced or metastatic urothelial cancer. MedDRA version: 20.0 Level: LLT Classification code 10046714 Term: Urothelial carcinoma bladder System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046723 Term: Urothelial carcinoma ureter System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046728 Term: Urothelial carcinoma urethra System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10077056 Term: Urothelial carcinoma recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10077840 Term: Urothelial cancer of renal pelvis System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046715 Term: Urothelial carcinoma bladder recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046721 Term: Urothelial carcinoma bladder stage III System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046722 Term: Urothelial carcinoma bladder stage IV System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046725 Term: Urothelial carcinoma ureter metastatic System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046726 Term: Urothelial carcinoma ureter recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046730 Term: Urothelial carcinoma urethra metastatic System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046731 Term: Urothelial carcinoma urethra recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, United States
- 2018-06-13
Authorised
- A study of enfortumab vedotin in patients with locally advanced or metastatic urothelial bladder cancer
- Patients with locally advanced or metastatic urothelial cancer. MedDRA version: 20.0 Level: LLT Classification code 10046714 Term: Urothelial carcinoma bladder System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046723 Term: Urothelial carcinoma ureter System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046728 Term: Urothelial carcinoma urethra System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10077056 Term: Urothelial carcinoma recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10077840 Term: Urothelial cancer of renal pelvis System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046715 Term: Urothelial carcinoma bladder recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046721 Term: Urothelial carcinoma bladder stage III System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046722 Term: Urothelial carcinoma bladder stage IV System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046725 Term: Urothelial carcinoma ureter metastatic System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046726 Term: Urothelial carcinoma ureter recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046730 Term: Urothelial carcinoma urethra metastatic System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046731 Term: Urothelial carcinoma urethra recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, United States
- 2018-05-22
Authorised
- A randomized, blinded clinical study comparing the combination durvalumab and olaparib to durvalumab alone for patients with advanced bladder cancer
- Unresectable Stage IV Urothelial Cancer MedDRA version: 20.0 Level: LLT Classification code 10022880 Term: Invasive bladder cancer stage IV System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2018-03-14
Authorised
- A study of nivolumab in participants with metastatic or unresectable bladder cancer
- metastatic or unresectable urothelial cancer MedDRA version: 19.0 Level: LLT Classification code 10046723 Term: Urothelial carcinoma ureter System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10046714 Term: Urothelial carcinoma bladder System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10046728 Term: Urothelial carcinoma urethra System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Czech Republic, Finland, Germany, Italy, Japan, Poland, Spain, Sweden, United States
- 2014-12-11
Authorised
- PHASE III RANDOMIZED CHEMOPREVENTION STUDY OF SELENIUM ON THE RECURRENCE OF NON-INVASIVE BLADDER CANCER - Seleblat
- Bladder cancer br>MedDRA version: 9.1 Level: LLT Classification code 10005014 Term: Bladder carcinoma br>MedDRA version: 9.1 Level: LLT Classification code 10005003 Term: Bladder cancer br>MedDRA version: 9.1 Level: LLT Classification code 10005004 Term: Bladder cancer NOS
- Belgium
- 2008-09-15
